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Cancer cell metabolism is often characterized by a shift from an oxidative to a glycolytic bioenerget-
ics pathway, a phenomenon known as the warburg effect. Whether the deregulation of miRNAs con-
tributes to the warburg effect remains largely unknown. Here we show that miR-181a expression is
increased and thus induces a metabolic shift in colon cancer cells. miR-181a performs this function
by inhibiting the expression of PTEN, leading to an increase of phosphorylated AKT which triggers
metabolic shift. The increase of lactate production induced by miR-181a results in the rapid growth
of cancer cells. These results identify miR-181a as a molecular switch involved in the orchestration
of the warburg effect in colon cancer cells via the PTEN/AKT pathway.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Mature miRNAs directly bind with their target genes via se-The metabolism of cancer cells is signiﬁcantly different from
that of normally differentiated cells [1]. Normally differentiated
cells rely primarily on the oxidation of pyruvate in the mitochon-
dria to generate energy for cellular physiology; however, even with
sufﬁcient oxygen, rapidly growing cancer cells rely on aerobic gly-
colysis to generate energy. This phenomenon is termed ‘‘the War-
burg effect’’ [2]. This metabolic shift towards enhanced glycolysis
is believed to be the result of adaptations to support the continu-
ous proliferation of cancer cells. Flux along other key metabolic
pathways, such as the glutaminolysis pathway, is also elevated
[3]. There is a growing body of evidence indicating that repro-
grammed cancer metabolism is a potential therapeutic target.
microRNAs (miRNAs) are an evolutionarily conserved group of
small non-coding RNAs (18–24 nucleotides) that suppress gene
expression [4]. miRNA genes are usually transcribed by RNA poly-
merase II as longer miRNA precursors called pri-miRNAs. Once
transcribed, pri-miRNAs are recognized by Drosha and processed
into pre-miRNAs, which are exported from the nucleus to the
cytoplasm through the protein Exportin-5. In the cytoplasm, pre-
miRNAs are cleaved into mature miRNAs by Dicer endonucleases.quence-speciﬁc interactions with 30 untranslated regions (UTR) of
cognate mRNA targets, resulting in suppression of mRNA transla-
tion or mRNA decay [5].
miRNAs are now known as essential regulators of development
and physiological processes. By regulating oncogenic and tumor
suppressor signal pathways, miRNAs might also play signiﬁcant
roles in cancer development. Recently, a large number of miRNAs
were identiﬁed as important natural regulators of metabolism
[6]. For example, miR-33a and miR-33b play a key role in regulat-
ing fatty acid degradation and cholesterol homeostasis by acting in
concert with their host genes, the sterol-regulatory element-
binding protein (SREBP) transcription factors [7]; numerous miR-
NAs, (e.g., miR-21, miR-143, miR-130, miR-27a) are reported to
be involved in white-adipocyte differentiation [8]; and inhibition
of miR-122 is thought to decrease plasma triglyceride and choles-
terol concentrations [9].
Aberrant expression of miR-181a has been reported in several
types of cancer and appears to be signiﬁcantly associated with
the clinical outcome of human cancer patients. For example,
miR-181a is signiﬁcantly downregulated in primary glioblastomas
and in non-small cell lung cancers [10,11], but it is signiﬁcantly
overexpressed in breast cancer cells, hepatocellular carcinoma
cells, and human gastric cancer tissues [12–14]. Overexpression
of miR-181a is correlated with lymph node metastasis, vascular
invasion, and poor survival [15].
The direct role of miR-181a in metabolism has not yet been
reported. In this study, we found that miR-181a is overexpressed
Fig. 1. miR-181a is overexpressed in colon cancer. (A) Heatmap of selected miRNA
expression in colon cancer cells compared with selected miRNA expression in
normal tissue. T: tumor; N: normal tissue. (B) Real-time PCR analysis of miR-181a
content in colon cancer tissue compared with miR-181a content in normal colon
tissue.
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enhanced cell proliferation through increased glycolysis. A lucifer-
ase reporter assay showed that miR-181a suppressed PTEN expres-
sion by directly targeting its 30-UTR, thus resulting in increased
AKT phosphorylation. These data suggest that miR-181a causes
an increase in lactate production and promotes cell proliferation
through the PTEN/AKT pathway.
2. Materials and methods
2.1. Cell culture and tissue samples
HCT15 and HCT116 colon cancer cells were purchased from the
American Type Culture Collection (ATCC). HCT15 and HCT116 cells
were cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM;
Invitrogen, California) supplemented with 10% fetal bovine serum
(FBS; Invitrogen, California), 4.5 g/L glucose, and 100 units/ml
penicillin/streptomycin in a tissue incubator maintained at 37 C,
5% CO2, and 90% humidity. LY294002 and 2-DG were obtained
from Sigma–Aldrich and dissolved in dimethyl sulfoxide (DMSO).
Colon cancer and adjacent non-tumor tissue samples were col-
lected from patients undergoing surgical resection at the Shanghai
Jiao Tong University Afﬁliated Sixth People’s Hospital. The specimens
were immediately frozen and stored at 80 C in an ultra-low-
temperature freezer. Pathological examination and quantitative
real-time PCR were used to conﬁrm cancer diagnosis.
2.2. Transfections
All transfections were performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. The miR-181a inhibitor, the negative controls and
the miR-181a mimics were purchased from GenePharma (China,
Shanghai). The miR-181a inhibitor and the miR-181a mimics were
used at a ﬁnal concentration of 50 nM.
2.3. Luciferase reporter assay
For the luciferase reporter assay, 293T cells were seeded in a 24-
well plate and grown to 80–90% conﬂuence. Lipofectamine 2000
was then used to cotransfect cells with either 50 nM aliquots of
the miR-181a mimics or 50 nM aliquots of a scramble and either
40 ng of pmirGLO-PTEN-30UTR-WT or 40 ng of pmirGLO-PTEN-
30UTR-MUT, according to the manufacturer’s instructions. After
48 h, the cells were collected and lysed with a passive lysis buffer
and then analyzed using a Dual-Luciferase Reporter Assay System
(Promega). Luciferase activity was detected using a M200 micro-
plate ﬂuorescence reader. The constitutive expression of Renilla
luciferase was used as an internal control to correct for differences
in harvest efﬁciencies and transfection. Transfections were per-
formed in duplicate and repeated in at least three independent
experiments.
2.4. RNA extraction and real-time PCR
The culture medium was removed, and the cells were immedi-
ately washed with ice-cold PBS. Subsequently, 1 ml of TRIzol re-
agent was added. and the cellular RNA was extracted according
to the acid guanidinium thiocyanate-phenol–chloroform method.
MMLV-RT reactions were used to synthesize cDNA from 1 lg of to-
tal RNA according to the manufacturer’s instructions. Real-time
quantitative reactions were performed in triplicate in a 96-well
plate containing 1 ll of synthesized cDNA, SYBR Green PCR mix,
and gene-speciﬁc forward and reverse PCR primers. The results
were normalized using b-actin. The melting curves were analyzedto verify the speciﬁcity of the RT-PCR reaction and the absence of
primer dimer formation. The primers used for detection are as fol-
lows: mTOR-F: 50-TCGCTGAAGTCACACAGACC-30; mTOR-R: 50-CTT
TGGCATATGCTCGGCAC-30; rictor-F: 50-ACAACTGGGATGCTGTGAG
G-30; rictor-R: 50-CCAAACCGGTCATCCTCCAA-30; mSin-F: 50-TTGGC
CCACAGAAAGGATGG-30; mSin-R: 50-TGAGCTGTGTTTGAGCGTCT-
30; mLST8-F: 50-GGTGAATGCCTTGGAGGTCA-30; mLST8-R: 50-TGCG
TTCACCTGGAAGATCC-30; PRR5-F: 50-AGTTCATGAGTTCGCCCAGC-
30; PRR5-R: 50-GTGAAGAAGGACCCCAGCTC; PTEN-F: 50-GTGGTC
TGCCAGCTAAAGGT-30; PTEN-R: 50-TCACCACACACAGGTAACGG-30.
For a quantiﬁcation of miRNAs, a TaqManMicroRNA reverse tran-
scription kit was used according to the manufacturer’s instructions.
The results were normalized to RNU48. The stem-loop primers
used for miR-181a and RNU48 are as follows: miR-181a-stem-loop
primer: 50-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATAC
GACACTCAC-30; miR-181a-F: 50-GCGGCGAACATTCAACGATG-30; miR-
181a-R: 50-GTGCAGGGTCCGAGG-30; RNU48-F: 50-TGATGATGACCC
CAGGTAACTC-30; RNU48-R: 50-GAGCGCTGCGGTGATG-30.
2.5. Western blots
Protein was harvested with RIPA buffer, quantiﬁed, and then re-
solved on an SDS–PAGE gel. The protein was then transferred onto
a membrane, which was blocked and incubated with an appropri-
ate primary antibody. After being washed, the membranes were
incubated with a secondary antibody. After three more washes,
the proteins were detected by chemiluminescence.
Fig. 2. miR-181a promotes the proliferation of colon cancer cells. (A) Real-time PCR analysis of miR-181a expression in HCT15 and HCT116 cancer cells transfected with miR-
181a mimics or a miR-181 inhibitor. (B) CCK8 assay results show that the growth rate of miR-181a-overexpressing colon cancer cells is faster that the growth rate of control
cells. (C) CCK8 assay results show that the growth rate of miR-181a knockdown colon cancer cells is slower that the growth rate of control cells. (D) Western blot assays show
that cyclin D1 expression is induced by miR-181a in colon cancer cells.
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Five-thousand cells/well were seeded into a 96-well plate and
treated with miR-181a mimics or a miR-181a inhibitor. After incu-
bation for 24 h, 48 h, 72 h, or 96 h, the cells were labeled with Cell
Counting Kit-8 (CCK8) (DOJINDO. Tabaru, JAPAN) for 2 h. Cell via-
bility was measured at an absorbance of 450 nm.
2.7. Measurement of extracellular lactate
Fifty-thousand cells that had been transfected with miR-181a
mimics or a miR-181a inhibitor were seeded in 60-mm dishes
and incubated in DMEM with 10% FBS overnight. Then, the mediawas removed, and the cells were incubated in DMEM without FBS.
After incubation for 1 h, the supernatant was collected. The con-
centration of lactate in the supernatant was quantiﬁed using a col-
orimetric assay according to the manufacturer’s instructions
(Lactate Assay Kit, Biovision).
2.8. Measurement of glucose uptake
After 12 h of serum starvation, cells were cultured in DMEM
containing 25 mM glucose. To measure the rate of glucose uptake,
the cells were washed three times with PBS and then incubated for
3 h in DMEM containing 1 mCi/ml 2-deoxy-2[1,2-3H] glucose
(PerkinElmer Life Sciences). The cells were washed three times
1776 Z. Wei et al. / FEBS Letters 588 (2014) 1773–1779with ice-cold PBS and solubilized in 1% SDS. A scintillation counter
was used to determine the radioactivity of each aliquot. Each assay
was performed in triplicate.
2.9. Statistical analyses
Statistical analysis was performed with GraphPad Prism 5
software. Student’s t-tests were used to determine statistical
signiﬁcance. The signiﬁcance level was set at P < 0.05 for all
analyses.
3. Results
3.1. miR-181a is overexpressed in colon cancer
First, we analyzed the miRNA expression proﬁle from a previ-
ously published dataset (Gene expression omnibus accession
GSE7828) and found that miR-181a was overexpressed in colon
cancers (Fig. 1A). Next, we conﬁrmed the expression of miR-181a
in colon cancer tissues. qRT-PCR analysis showed that among eight
matched sample pairs, miR-181a expression was signiﬁcantly
higher in all clinical colon cancer tissues compared with adjacent
non-tumor tissue acquired from a site 4 cm away from the tumor’s
margin (Fig. 1B).
3.2. miR-181a promotes the proliferation of colon cancer cells
To assess the role of miR-181a in the growth of colon cancer
cells, we transfected HCT15 and HCT116 colon cancer cells with
50 nM aliquots of miR-181a mimics or 50 nM aliquots of aFig. 3. miR-181a induces a metabolic shift in colon cancer cells. (A) Lactate production
show that miR-181a increases the rate of glucose uptake. (C) Western blot assays show th
(D) CCK8 assays show that inhibition of glycolysis with 2-DG blocks miR-181a-inducedmiR-181a inhibitor. The qRT-PCR analysis revealed that miR-181a
expression was dramatically and speciﬁcally increased in the mi-
mic-transfected cells and decreased in the inhibitor-transfected
cells (Fig. 2A). A CCK8 assay showed that cell proliferation was
greater in miR-181a-overexpressing colon cancer cells than in
the control cells (Fig. 2B). We then asked whether reducing miR-
181a in colon cancer cells inhibited cell proliferation. To address
this question, we treated HCT116 and HCT15 cancer cells with a
miR-181a inhibitor. As expected, loss of miR-181a function atten-
uated cell proliferation (Fig. 2C).
To further explore the effect of miR-181a on cell cycle progres-
sion, we used Western blot analysis to demonstrate that overex-
pression of miR-181a enhanced the level of cyclin D1, a critical
cell cycle component (Fig. 2D). Taken together, these results sug-
gest that miR-181a enhanced cell proliferation.
3.3. miR-181a induces a metabolic shift in colon cancer cells
We next sought to determine whether miR-181a was capable of
inducing a metabolic shift in colon cancer cells. Induction of miR-
181a in colon cancer cells increased glucose uptake and lactate
secretion (Fig. 3A and B). Conversely, the use of an inhibitor to
knockdown miR-181a expression reduced lactate secretion and
glucose uptake (Fig. 3A and B). Glut1 and HK2 are key cell glycol-
ysis genes. Western blot analysis showed that miR-181a increased
the expression of Glut1 and HK2 (Fig. 3C).
To determine whether a miR-181a-induced metabolic switch is
required for miR-181a-dependent cell proliferation, we treatedmiR-
181a mimic-transfected HCT116 cancer cells with 2-deoxyglucose
(2-DG), a glucose analog that inhibits glycolysis via its action onassays show that miR-181a stimulates lactate secretion. (B) Glucose uptake assays
at the expression of HK2 and Glut1 is upregulated in miR-181a overexpressing cells.
increases in colon cancer cell proliferation.
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sults demonstrated that inhibition of miR-181a-induced glycolysis
is sufﬁcient to block miR-181a-induced cell proliferation (Fig. 3D).
Taken together, these results suggest that miR-181a-induced glycol-
ysis is responsible for the observed increase in colon cancer cell
proliferation.
3.4. Phosphorylated AKT is required for the metabolic shift induced by
miR-181a
Previous reports have demonstrated that hypoxia inducible fac-
tors (HIFs) and the proto-oncogene c-Myc play a central role in reg-
ulating cell glycolysis. We detected HIF1-a and c-Myc protein
levels in two miR-181a-overexpressing cell lines: HCT15 and
HCT116. Western blot analysis revealed no differences in the pro-
tein expression of HIF1-a and c-Myc between miR-181a-over-
expressing colon cancer cells and control cells (Fig. 4A). Recent
studies have indicated that miR-181a expression increases Erk1/
2, AKT, and Src signaling in breast cancer cells. In addition, AKT
activity renders cancer cells dependent on aerobic glycolysis for
continued growth and survival [15,16]. Therefore, we hypothesized
that miR-181a would stimulate cancer cell glycolysis by increasing
AKT activity. Consistent with this prediction, overexpression of
miR-181a in colon cancer cells was sufﬁcient to induce AKT S473
phosphorylation without affecting the total AKT level (Fig. 4A).
These data suggest that increased miR-181a expression is associ-
ated with an increase in AKT S473 phosphorylation. To determine
whether AKT activity might account for the metabolic shift in-
duced by miR-181a, we treated miR-181a-overexpressing cells
with LY294002, a cell-permeable speciﬁc phosphatidylinositol
3-kinase inhibitor. Western blot analysis showed that LY294002
signiﬁcantly inhibits the phosphorylation of AKT and decreasesFig. 4. Phosphorylated AKT is required for the miR-181a-induced metabolic shift. (A) W
affect total AKT, c-Myc, or HIF1-a expression. (B) Western blot assays show that inhibitio
HK2 and Glut1. (C) Inhibition of AKT phosphorylation with LY294002 suppresses miR-181
LY294002 suppresses miR-181a-induced increases in the rate of glucose uptake.miR-181a-induced expression of Glut1 and HK2 (Fig. 4B). These
data indicate that the inhibition of AKT activity in miR-181a-over-
expressing cells is sufﬁcient to decrease colon cancer-induced
alterations in the rate of glycolysis via a reduction of Glut1 and
HK2 expression. Furthermore, LY294002 inhibited the increased
rate of glucose and lactate production observed in miR-181a-
overexpressing cells (Fig. 4C and D). These data suggest that
AKT activity is required for miR-181a-induced changes in
glycolysis.
3.5. miR-181a suppresses expression of PTEN
Three different mRNA target-predicting algorithms (TargetScan,
miRanda, and targetRank) were used to identify potential direct
targets of miR-181a based on binding sites in the 30UTR. We se-
lected candidate genes that were associated with AKT phosphory-
lation. mRNA target-predicting algorithms identiﬁed an area
within the 30UTR of PTEN as a potential target of miR-181a.
qRT-PCR analysis was used to verify PTEN as a target of miR-
181a. mRNA expression of PTEN was decreased in miR-181a-over-
expressing cells; however, there were no signiﬁcant changes in the
mRNA expression of the essential components of mTORC2 (i.e.,
mTOR, rictor, mSin1, mLST8, PRR5), which phosphorylates mem-
bers of the AGC kinase family, including AKT (Fig. 5A). Western blot
analysis also conﬁrmed that expression of miR-181a decreased the
protein level of PTEN (Fig. 5B).
To further determine whether PTEN is a direct target of miR-
181a, we constructed a wild-type dual-luciferase UTR vector that
contained the 30UTR of PTEN and a mutant dual-luciferase UTR vec-
tor that harbored mutations in the miR-181a binding sites of the
30UTR of PTEN (PTEN-mut) (Fig. 5C). As expected, miR-181a effec-
tively suppressed the luciferase reporter activity of the wild-typeestern blot assays show that miR-181a increases AKT phosphorylation but does not
n of AKT phosphorylation with LY294002 blocks miR-181a-induced upregulation of
a-induced increases in lactate secretion. (D) Inhibition of AKT phosphorylation with
Fig. 5. miR-181a suppresses expression of PTEN. (A) Real-time PCR shows that overexpression of miR-181a signiﬁcantly downregulates mRNA expression of PTEN but does
not affect mRNA expression of mTORC2 components. (B) Western blot assays suggest that overexpression of miR-181a suppresses the PTEN expression. (C) This sequence in
the 30UTR of PTEN was predicted to bind to miR-181a. The nucleotides in res were mutated into their complementary nucleotides in Mut 30UTR. (D) Dual-luciferase assays
show that miR-181a suppresses luciferase activity in cells containing the 30UTR wild type vector, but miR-181a does not affect luciferase activity in cells containing the 30UTR
mutant vector.
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when cells were transfected with the mutant vector (Fig. 5D).
Taken together, these results demonstrate that miR-181a directly
regulates PTEN expression through binding sites in the 30UTR.
4. Discussion
miRNAs have attracted increased attention due to their key
role in many biological events, including cell proliferation, cell
motility, differentiation, and apoptosis [17]. In recent years, the
dysregulation of miR-181a has been associated with a variety of
human cancers. Signiﬁcant miR-181a downregulation has been re-
ported in primary glioblastomas, squamous cell cancers, and non-
small cell lung carcinomas. However, signiﬁcant miR-181a overex-
pression has been reported in MCF-7 breast cancer cells, human
gastric cancer tissues, and HCC cells. Therefore, the function of
miR-181a in tumorigenesis remains unclear.
In this study, we found that miR-181a expression was higher in
colon cancer tissues compared with adjacent normal tissues
(Fig. 1B). This elevation was consistent with the miRNA proﬁle dif-
ferences between colon adenocarcinomas and paired non-tumor-
ous colon cells (GSE7828). Previous reports have demonstrated
that miR-181a promotes gastric cancer cell proliferation and col-
ony formation in vitro and HCC xenograft growth in nude mice
[14]. Therefore, we hypothesized that miR-181a may act as an
oncomir to enhance cell proliferation. The results of the CCK8 assay
indicated that miR-181a promoted cell proliferation (Fig. 2B and
C). Cyclin D1, a cell cycle checkpoint protein [18], was also upreg-
ulated in miR-181a-overexpressing cells, further conﬁrming that
miR-181a regulated cell growth. However, further study is re-
quired to determine how miR-181a inﬂuences the expression of
Cyclin D1.
The molecular mechanisms responsible for shifting energy
metabolism to the advantage of cancer cells are complex and only
partially understood. In this study, we demonstrated that miR-
181a plays an important role in reprogramming the metabolism
of colon cells. Overexpression of miR-181a increases glucoseuptake and lactate secretion, while knockdown of miR-181a
decreases glucose uptake and lactate secretion (Fig. 3A and B).
The altered metabolism induced by miR-181a is required for
cancer cell growth (Fig. 3D).
Moreover, we found that PTEN is a direct target of miR-181a.
The suppression of PTEN increases AKT S473 phosphorylation,
which is involved in glycolysis [19]. Inhibition of AKT S473 phos-
phorylation with LY294002 blocks miR-181a-induced glycolysis
(Fig. 4C and D). Previous reports have demonstrated that mTORC2
regulates cell glycolysis by phosphorylating AKT [19], but in this
study, we found no signiﬁcant changes in the critical components
of mTORC2, including mTOR, rictor, mSin1, mLST8, and PRR5. Like-
wise, we did not detect signiﬁcant changes in the expression of
c-Myc and HIF1-a, both of which are well-established transcrip-
tional factors. Dysregulation of miR-181a in colon cancers has been
extensively investigated for its role in aerobic glycolysis.
In summary, our study provides direct evidence that miR-181a
promotes colon cancer cell glycolysis through the miR-181a-PTEN-
AKT cascade, thus promoting cell proliferation. These results iden-
tify miR-181a as a molecular switch involved in the orchestration
of the Warburg effect in colon cancer cells and as a potential ther-
apeutic target for colon cancer.
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